Thus, CBP/p300 dual inhibitors could be promising for SMARCA4/SMARCA2-deficient lung cancer and SS18–SSX fusion synovial sarcoma, which are entirely deficient in the cBAF complex. This evidence concerns the gene CREBBP and synovial sarcoma.